Retatrutide vs Tirzepatide

Retatrutide is an experimental triple-receptor drug (GIP, GLP-1, and glucagon) that has not yet been approved for any use, while Tirzepatide (sold as Mounjaro or Zepbound) is an FDA-approved dual-receptor drug (GIP and GLP-1) used to treat type 2 diabetes, obesity, and obstructive sleep apnea. Tirzepatide is available now as an injection, whereas Retatrutide is still in clinical trials and not yet on the market.

AI summary of the sources below.